Market Insights
According to the Cleveland Clinic, aspergillosis is an infection or allergic reaction caused by various kinds of molds found on plants, soil, building materials, or rotting vegetables. The aspergillosis treatment market can be segmented on the basis of several types, such as allergic bronchopulmonary aspergillosis (ABPA), allergic Aspergillus sinusitis, aspergilloma, chronic pulmonary aspergillosis, invasive aspergillosis, and cutaneous (skin) aspergillosis.
ABPA is observed as one of the most common aspergillosis types in which inflammation in the lungs and allergy symptoms such as coughing and wheezing are observed. ABPA is treated with the delivery of steroids such as prednisolone through aerosol during the attacks; in some cases, itraconazole is also used to reduce the dose of steroids. ABPA usually affects people suffering from asthma and cystic fibrosis; around 1 in every 40 people with asthma may be affected by ABPA.
Invasive aspergillosis is the most severe type of aspergillosis as the infection travels from the lung to the bloodstream, infecting other organs such as the kidneys, liver, skin, or brain; it is mostly observed in people with low immunity. Invasive aspergillosis is treated with voriconazole, caspofungin, micafungin, itraconazole, amphotericin B, or posaconazole. Medical practitioners suggest that prophylactic antifungal therapy accompanied by the use of laminar airflow (LAF) or high-efficiency particulate air (HEPA) filtration in patient rooms can prevent the risk of aspergillosis, especially in patients who receive organ transplants.
The recent FDA approval received by isavuconazole (Cresemba) for invasive aspergillosis in March 2015 is considered a major boost to the aspergillosis treatment market in the near future. Approval was based on the SECURE study (n = 516) that demonstrated isavuconazole as non-inferior to voriconazole on the primary endpoint of all-cause mortality at day 42 for the treatment of adult patients with invasive aspergillosis or other filamentous fungi (isavuconazole 18.6% vs. voriconazole 20.2%). The report also suggested that isavuconazole has activity against most strains of the following microorganisms, both in vitro and in clinical infection: Aspergillus niger, Aspergillus fumigatus, and Aspergillus flavus.
The aspergillosis treatment market can be segmented on the basis of drug class, such as antifungal and corticosteroids. Antifungals can be further classified as voriconazole, itraconazole, caspofungin, micafungin, amphotericin B, and isavuconazole. The corticosteroids that are highly preferred in aspergillosis treatment are prednisolone, prednisone, and methylprednisolone. The prevalence of aspergillosis is about 1–2 per 100,000 people every year.
The global aspergillosis treatment market is segmented on the following basis:
Type of Aspergillosis
- Allergic Bronchopulmonary Aspergillosis (ABPA)
- Allergic Aspergillus Sinusitis
- Aspergilloma
- Chronic pulmonary aspergillosis
- Invasive Aspergillosis
- Cutaneous (skin) Aspergillosis
Type of Drug Class
- Antifungal
- Voriconazole
- Itraconazole
- Caspofungin
- Micafungin
- Amphotericin B
- Isavuconazole
- Corticosteroids
- Prednisolone
- Prednisone
- Methylprednisolone
Geography
- North America
- Europe
- Germany
- France
- Italy
- U.K.
- Russia
- Rest of Europe
- Asia-Pacific
- India
- China
- Japan
- Rest of Asia-Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Key players identified for the aspergillosis treatment market include but are not limited to:
The key players in the market are Pfizer Inc., Astra Zeneca Plc, Merck & Co., GlaxoSmithKline, Mylan Pharmaceuticals, Inc., Novartis AG, Abbott Laboratories, Inc., Takeda Pharmaceutical Company Ltd., Janssen Global Services, LLC (a subsidiary of Johnson & Johnson Services, Inc.), Basilea Pharmaceutica Ltd., and others.
This report offers the following:
-
-
- An overview of the global markets for aspergillosis treatment
- Market trends assessment for the period 2013-2023, with historical information for 2013, 2014, and 2015, and projections through 2023, with respective CAGRs during 2016-2023
- Qualitative assessment tools such as market drivers, challenges, and opportunities
- Market competition scrutiny tools such as market share analysis, fractal map assessment, and Porter’s Five Forces model
- Focus on each level of market segmentation based on product approvals, launches, and current and anticipated market dynamics.
- A general overview of the industry structure
- Company profiles highlight key information about the major players operating in the aspergillosis treatment market.
